Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1Breast 1

Conditions

Breast Neoplasms 40Triple Negative Breast Neoplasms 34Carcinoma, Non-Small-Cell Lung 11Carcinoma, Transitional Cell 10Urinary Bladder Neoplasms 9Neoplasm Metastasis 8Lung Neoplasms 5Brain Neoplasms 5Endometrial Neoplasms 4Small Cell Lung Carcinoma 3Ovarian Neoplasms 3Glioblastoma 3Uterine Cervical Neoplasms 2Salivary Gland Neoplasms 2Pancreatic Neoplasms 2Esophageal Neoplasms 2Colorectal Neoplasms 2Carcinoma, Ovarian Epithelial 2Advanced Breast Cancer 2Uterine Neoplasms 1Urothelial Bladder Carcinoma 1Triple Negative Locally Advanced Non-resectable Breast Cancer 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1Recurrence 1Prostatic Neoplasms, Castration-Resistant 1

Interventions

Pemetrexed 20Bevacizumab 10Radiotherapy 8Spinal Puncture 7osimertinib 6Methotrexate 6Magnetic Resonance Spectroscopy 6aflutinib 5Topotecan 5Specimen Handling 5Trastuzumab 4Temozolomide 4Radiotherapy, Intensity-Modulated 4Dexamethasone 3trastuzumab deruxtecan 2pembrolizumab 2paclitaxel-Angiopep-2 conjugate 2omburtamab I-131 2merphos 2lorlatinib 2aumolertinib 2WP 744 2Vitamin B 12 2Rituximab 2Radiation 2Folic Acid 2Drug Therapy 2Cytarabine 2Cyclophosphamide 2Capecitabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Meningeal Carcinomatosis × sacituzumab govitecan × Clear all
NCT06462092 2025-09-29

Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer

Guangzhou Medical University

Phase 1/2 Recruiting
34 enrolled
BreastCNS

Breast Neoplasms, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡